{"Title": "Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial", "Year": 2020, "Source": "J. Clin. Oncol.", "Volume": "38", "Issue": 5, "Art.No": null, "PageStart": 423, "PageEnd": 433, "CitedBy": 33, "DOI": "10.1200/JCO.19.00368", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85077439423&origin=inward", "Abstract": "Copyright \u00a9 2020 American Society of Clinical Oncology. All rights reserved.PURPOSE The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN. The PAKT trial was designed to evaluate the safety and efficacy of adding capivasertib to paclitaxel as first-line therapy for TNBC. PATIENTS AND METHODS This double-blind, placebo-controlled, randomized phase II trial recruited women with untreated metastatic TNBC. A total of 140 patients were randomly assigned (1:1) to paclitaxel 90 mg/m2 (days 1, 8, 15) with either capivasertib (400 mg twice daily) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), PFS and OS in the subgroup with PIK3CA/AKT1/PTEN alterations, tumor response, and safety. RESULTS Median PFS was 5.9 months with capivasertib plus paclitaxel and 4.2 months with placebo plus paclitaxel (hazard ratio [HR], 0.74; 95% CI, 0.50 to 1.08; 1-sided P = .06 [predefined significance level, 1-sided P = .10]). Median OS was 19.1 months with capivasertib plus paclitaxel and 12.6 months with placebo plus paclitaxel (HR, 0.61; 95% CI, 0.37 to 0.99; 2-sided P = .04). In patients with PIK3CA/AKT1/PTEN-altered tumors (n = 28), median PFS was 9.3 months with capivasertib plus paclitaxel and 3.7 months with placebo plus paclitaxel (HR, 0.30; 95% CI, 0.11 to 0.79; 2-sided P = .01). The most common grade $ 3 adverse events in those treated with capivasertib plus paclitaxel versus placebo plus paclitaxel, respectively, were diarrhea (13% v 1%), infection (4% v 1%), neutropenia (3% v 3%), rash (4% v 0%), and fatigue (4% v 0%). CONCLUSION Addition of the AKT inhibitor capivasertib to first-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. Benefits were more pronounced in patients with PIK3CA/AKT1/PTEN-altered tumors. Capivasertib warrants further investigation for treatment of TNBC.", "AuthorKeywords": null, "IndexKeywords": ["Adult", "Aged", "Antineoplastic Combined Chemotherapy Protocols", "Class I Phosphatidylinositol 3-Kinases", "Double-Blind Method", "Female", "Humans", "Middle Aged", "Paclitaxel", "Placebos", "Progression-Free Survival", "Proto-Oncogene Proteins c-akt", "PTEN Phosphohydrolase", "Pyrimidines", "Pyrroles", "Signal Transduction", "Triple Negative Breast Neoplasms"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85077439423", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"57203057134": {"Name": "Schmid P.", "AuthorID": "57203057134", "AffiliationID": "60159931", "AffiliationName": "Barts Hospital NHS Trust"}, "23012898100": {"Name": "Sarker S.J.", "AuthorID": "23012898100", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "57210840427": {"Name": "Prendergast A.", "AuthorID": "57210840427", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "57215122064": {"Name": "McLaughlin-Callan M.", "AuthorID": "57215122064", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "54406488300": {"Name": "Burgess M.", "AuthorID": "54406488300", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "57193331648": {"Name": "Lawrence C.", "AuthorID": "57193331648", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "57215112239": {"Name": "Cartwright H.", "AuthorID": "57215112239", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "56845484000": {"Name": "Mousa K.", "AuthorID": "56845484000", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts ECMC, Barts Cancer Institute, Queen Mary University of London"}, "57215140550": {"Name": "Phillips M.", "AuthorID": "57215140550", "AffiliationID": "60159931", "AffiliationName": "Barts Hospital NHS Trust"}, "54794902800": {"Name": "Conibear J.", "AuthorID": "54794902800", "AffiliationID": "60159931", "AffiliationName": "Barts Hospital NHS Trust"}, "23134346800": {"Name": "Abraham J.", "AuthorID": "23134346800", "AffiliationID": "60026578", "AffiliationName": "Velindre National Health Service (NHS) Trust"}, "7404255219": {"Name": "Chan S.", "AuthorID": "7404255219", "AffiliationID": "60025016", "AffiliationName": "Nottingham University Hospitals NHS Trust"}, "35189905000": {"Name": "Wheatley D.", "AuthorID": "35189905000", "AffiliationID": "60012582", "AffiliationName": "Royal Cornwall Hospitals NHS Trust"}, "7003285780": {"Name": "Brunt A.M.", "AuthorID": "7003285780", "AffiliationID": "60004563", "AffiliationName": "University Hospitals of North Midlands NHS Trust"}, "57188567636": {"Name": "Nemsadze G.", "AuthorID": "57188567636", "AffiliationID": "101407268", "AffiliationName": "Institute of Clinical Oncology"}, "7201567425": {"Name": "Baird R.D.", "AuthorID": "7201567425", "AffiliationID": "60012754", "AffiliationName": "Cancer Research UK Cambridge Centre"}, "57215129582": {"Name": "Park Y.H.", "AuthorID": "57215129582", "AffiliationID": "60020857", "AffiliationName": "Samsung Medical Centre"}, "57207416747": {"Name": "Hall P.S.", "AuthorID": "57207416747", "AffiliationID": "60027272", "AffiliationName": "Edinburgh Cancer Research Centre, University of Edinburgh"}, "7003507783": {"Name": "Perren T.", "AuthorID": "7003507783", "AffiliationID": "60012508", "AffiliationName": "Leeds Teaching Hospitals NHS Trust"}, "7402952709": {"Name": "Stein R.C.", "AuthorID": "7402952709", "AffiliationID": "60024544, 60172674, 60022148", "AffiliationName": "National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, University College London"}, "57217761787": {"Name": "Mangel L.", "AuthorID": "57217761787", "AffiliationID": "60007508", "AffiliationName": "Institute of Oncology, Medical University of P\u00e9cs"}, "55666515400": {"Name": "Ferrero J.M.", "AuthorID": "55666515400", "AffiliationID": "60021628", "AffiliationName": "Centre Antoine Lacassagne"}, "7201403402": {"Name": "Cortes J.", "AuthorID": "7201403402", "AffiliationID": "121356299", "AffiliationName": "IOB institute of Oncology, Quiron Group"}, "57194868272": {"Name": "Foxley A.", "AuthorID": "57194868272", "AffiliationID": "60004219", "AffiliationName": "AstraZeneca"}, "7004058821": {"Name": "de Bruin E.C.", "AuthorID": "7004058821", "AffiliationID": "60004219", "AffiliationName": "AstraZeneca"}, "7004905397": {"Name": "McEwen R.", "AuthorID": "7004905397", "AffiliationID": "60004219", "AffiliationName": "AstraZeneca"}, "56613118000": {"Name": "Stetson D.", "AuthorID": "56613118000", "AffiliationID": "60004219", "AffiliationName": "AstraZeneca"}, "56613044000": {"Name": "Dougherty B.", "AuthorID": "56613044000", "AffiliationID": "60004219", "AffiliationName": "AstraZeneca"}, "35331494900": {"Name": "Turner N.C.", "AuthorID": "35331494900", "AffiliationID": "60027057", "AffiliationName": "Royal Marsden Hospital"}}}